SAN DIEGO, June 27, 2017 /PRNewswire/ -- Mirati
Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted
oncology biotechnology company, today announced the appointment of
Neil Reisman to the Company's Board
of Directors, effective immediately.
Mr. Reisman is a lawyer and Certified Public Accountant with
over 30 years of business experience with emphasis on finance,
operations, legal, tax and transactional experience. He will
provide similar guidance while serving on Mirati's Board of
Directors.
"Neil is an accomplished business leader and advisor," said
Charles M. Baum, M.D., Ph.D.,
President and Chief Executive Officer of Mirati Therapeutics. "We
are pleased to add his talents and extensive experience to our
Board of Directors and confident Mirati will benefit from his
insights and counsel."
Mr. Reisman is a managing director and member of the Tavistock
Group Board of Directors. He joined Tavistock in 2004 as Chief
Operating Officer/Chief Financial Officer/General Counsel at CovX,
a biotechnology company located in San Diego. Over the years, he has assumed
various operational roles at companies within Tavistock Group and
various other roles at the Tavistock Group, including chairing its
Investment Committee as well as having the offices of the
General Counsel and Chief Financial Officer report to him. He is
currently Chairman of the Board of Nucleus Biologics. Mr. Reisman
received his JD in 1986 from the University of
Pennsylvania Law School and his BS in Accountancy in 1983
from the University of Illinois.
About Mirati Therapeutics
Mirati Therapeutics is a clinical-stage biotechnology company
focused on developing a pipeline of targeted oncology products
intended to treat specific genetic and epigenetic drivers of
cancer. This approach is transforming the treatment of patients by
targeting the genetic changes in tumor cells that result in
uncontrolled tumor growth and migration. Our precision oncology
programs seek to treat the patients most likely to benefit from
targeted oncology treatments and are driven by drugs that target
very specific genetic mutations, directed by genomic tests that
identify patients who carry those driver mutations. Our
immuno-oncology programs are novel small molecule drugs designed to
enhance and expand the efficacy of checkpoint inhibitors when given
in combination. In addition to our clinical programs, we have
active discovery research efforts focused on novel oncology
targets. The promise of these approaches includes potentially
better patient outcomes, more efficient cancer treatment and faster
drug development. For more information, visit www.mirati.com.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/mirati-therapeutics-announces-appointment-of-neil-reisman-to-the-board-of-directors-300479794.html
SOURCE Mirati Therapeutics, Inc.